scholarly journals Effectiveness of the US Centers for Disease Control and Prevention HEADS UP coaches’ online training as an educational intervention

2019 ◽  
Vol 78 (7) ◽  
pp. 784-797 ◽  
Author(s):  
Jill Daugherty ◽  
Lara DePadilla ◽  
Kelly Sarmiento
Keyword(s):  
Disease Control ◽  
Online Training ◽  
Return To Play ◽  
Rank Test ◽  
The Us ◽  
Post Test ◽  
Control And Prevention ◽  
Signed Rank Test ◽  
Centers For Disease Control ◽  
High Level

Background: Concussions are common among youth athletes. Responsibility for the recognition and management of concussion is often put on coaches. To equip coaches with appropriate knowledge and skills, the US Centers for Disease Control and Prevention (CDC) launched the HEADS UP: Concussion in Youth Sports online training. Objectives: To determine whether HEADS UP coaches’ training improves knowledge, attitudes and behavioural intentions. Methods: Knowledge questions were grouped into scales by level of difficulty. Differences between pre- and post-test scores were calculated based on the Wilcoxon Signed Rank Test Z-score and effect sizes were interpreted. Results: Coaches displayed a high level of knowledge in the pre-test. While lower difficulty questions did not show improvement from pre- to post-test, moderate and high difficulty questions did. Use of the training was associated with improved knowledge about symptom resolution, return-to-play recommendations and under-reporting of incidents of concussion. Coaches demonstrated improvement in five of the seven concussion-related attitude and behavioural intention items post training. Conclusion: HEADS UP training improved coaches’ knowledge on select topics and helped them feel more comfortable about responding to concussion among their athletes. This study provides insight into how to better focus future HEADS UP concussion health education efforts to fit coaches’ informational needs.

scholarly journals The Effect of National Healthcare Safety Network (NHSN) Rebaselining on Community Hospital SIRs

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S50-S51
Author(s):  
Christopher Hostler ◽  
Rebekah W Moehring ◽  
Arthur W Baker ◽  
Becky Smith ◽  
Linda Adcock ◽  
...  
Keyword(s):  
Disease Control ◽  
Abdominal Hysterectomy ◽  
Rank Test ◽  
Meaningful Change ◽  
Signed Rank ◽  
Grant Recipient ◽  
Control And Prevention ◽  
Signed Rank Test ◽  
Centers For Disease Control ◽  
The Impact

Abstract Background The NHSN recently updated risk adjustment models and “rebaselined” Standardized Infection Ratios (SIRs) for healthcare-associated infections. The CDC expected that hospital SIRs would generally increase. However, the impact of rebaselining on individual hospitals’ SIRs was unknown. Accordingly, we assessed the impact of rebaselining on SIRs in a network of community hospitals. Methods We analyzed 2016 SIR data for CAUTI, MRSA LabID events, CDI LabID events, colon SSIs (COLO), and abdominal hysterectomy SSIs (HYST) from 38 hospitals in the Duke Infection Control Outreach Network (DICON). SIRs calculated using the old and new baselines were compared. Wilcoxon signed rank test was performed to determine whether hospitals’ SIRs changed significantly following rebaselining. Hospitals were ranked by SIR for each metric, and change in rank following rebaselining was determined. Meaningful change in rank was defined as increase or decrease by ≥4 places (greater than a decile). Hospitals that did not have an SIR calculated for a given metric were excluded from that metric’s analysis. Results Median hospital SIRs for CAUTI and CDI increased significantly after rebaselining (0.587 vs 0.307, P < 0.001; and 0.825 vs 0.783, p = 0.04, respectively). Median MRSA SIRs increased (0.903 vs 0.797, P = 0.5), and COLO and HYST SIRs decreased (0.457 vs 0.586, P = 0.1; and 0 vs 0.489, P = 0.4); however, these changes were not statistically significant (Figure 1). For all metrics, a minority of hospitals had meaningful change in SIR rank following rebaselining (Figure 2). Conclusion SIRs increased following rebaselining for CAUTI and CDI but did not change significantly for MRSA, COLO, or HYST. The majority of hospitals’ SIR rank did not change meaningfully following rebaselining. Disclosures D. Sexton, Centers for Disease Control and Prevention: Grant Investigator, Grant recipient; Centers for Disease Control and Prevention Foundation: Grant Investigator, Grant recipient; UpToDate: Collaborator, Royalty Recipient

scholarly journals CDC Warns of Increased Ivermectin Overdoses

2021 ◽  
Vol 23 (2) ◽  
pp. 62-63
Author(s):  
Richard Robbins ◽  
Keyword(s):  
Disease Control ◽  
River Blindness ◽  
The Us ◽  
Control And Prevention ◽  
Centers For Disease Control ◽  
In Cells

No abstract available. Article truncated after 150 words. The US Centers for Disease Control and Prevention (CDC) is warning of an increase in cases of ivermectin overdose due to people self-prescribing the drug in an effort to prevent or treat COVID-19 (1). Ivermectin is used to treat river blindness and intestinal roundworm infection in humans and to de-worm pets and livestock. A study published earlier this year showed that ivermectin killed SARS-CoV-2 in cells in vitro. The authors proposed that the medication be investigated as a cheap and easily available treatment for COVID-19. However, subsequent studies have failed to find any benefit in humans (3). In a new communication to its Health Alert Network, the CDC says cases of overdose and misuse are rising (1). More than 88,000 prescriptions were written for the drug ivermectin in the week ending August 13, an increase of 2400% over the weekly average prior to the COVID-19 pandemic (Figure 1). Unfortunately, the …

scholarly journals EU financial accounts reports

10.5912/jcb96 ◽  
2004 ◽  
Vol 10 (4) ◽  
Author(s):  
Colin Aaronson
Keyword(s):  
Research And Development ◽  
Disease Control ◽  
Smallpox Vaccine ◽  
Biotechnology Company ◽  
Stages Of Development ◽  
The Third ◽  
The Us ◽  
Development Expenditure ◽  
Control And Prevention ◽  
Centers For Disease Control

Acambis is a profitable and cash-generative biotechnology company that is focused on building a substantial franchise in the vaccine space. Its results for the period have benefited significantly from its contract to supply 155 million doses of its ACAM2000 smallpox vaccine to the US Centers for Disease Control and Prevention (CDC). During the year ended 31st December, 2003, Acambis generated profit before taxation (before exceptional items) of £46.8m on sales of £169.1m compared with a profit of £9.6m on sales of £79.7m for the whole of 2002. The pre-tax profit for the year was £39.4m, after taking account of an exceptional cost of £7.4m following a settlement with BTG International Limited to discharge all rights and obligations under a technology licence agreement established in 1994. The profit was earned mainly in the third quarter, with £22.2m earned during the three months ended 30th September, 2003, the company having earned £20.6m for the six months ended 30th June, 2003. Research and development expenditure increased from £16.5m in 2002 to £19.1m in 2003, the result of the progression of the company's products to the later stages of development.

Sign in / Sign up

Export Citation Format

Share Document